Winton Group LTD Lexicon Pharmaceuticals, Inc. Transaction History

Winton Group LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$1.95 - $3.89 $20,841 - $41,576	-10,688 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$3.81 - $6.16 $386,455 - $624,821	-101,432 Reduced 90.47%	10,688 $42,000
Q3 2021 Oct 28, 2021	SELL	$3.38 - $5.35 $122,295 - $193,573	-36,182 Reduced 24.4%	112,120 $539,000
Q2 2021 Aug 10, 2021	SELL	$4.12 - $5.87 $63,312 - $90,204	-15,367 Reduced 9.39%	148,302 $681,000
Q1 2021 Jul 21, 2021	SELL	$3.45 - $9.09 $100,812 - $265,618	-29,221 Reduced 15.15%	163,669 $961,000
Q4 2020 Feb 12, 2021	SELL	$1.05 - $3.67 $191,386 - $668,941	-182,273 Reduced 48.59%	192,890 $660,000
Q3 2020 Oct 30, 2020	BUY	$1.44 - $2.1 $58,250 - $84,949	40,452 Added 12.09%	375,163 $540,000
Q2 2020 Aug 05, 2020	BUY	$1.75 - $2.3 $295,750 - $388,699	169,000 Added 101.98%	334,711 $668,000
Q1 2020 May 11, 2020	BUY	$1.8 - $4.28 $298,279 - $709,243	165,711 New	165,711 $323,000
Q4 2019 Feb 13, 2020	SELL	$3.16 - $5.15 $75,328 - $122,765	-23,838 Closed	0 $0
Q3 2019 Nov 08, 2019	BUY	$1.2 - $6.66 $28,605 - $158,761	23,838 New	23,838 $72,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $157M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.